Reducing Pharmaceutical Prices Requires Competition, Not Price-Fixing
Cutting the red tape around biosimilars is one way that the administration can protect U.S. drug innovation and make medicine more affordable for Americans.
Cutting the red tape around biosimilars is one way that the administration can protect U.S. drug innovation and make medicine more affordable for Americans.